Cover Image
Market Research Report
Product code 
1063799

Peptide Therapeutics: Contract API Manufacturing Market by Scale of Operation (Preclinical / Clinical and Commercial), Type of Synthesis Method Used (Chemical Synthesis Method and Non-Chemical Synthesis Method),

Published: | Roots Analysis | 294 Pages | Delivery time: 1-2 business days

Price

Back to Top
Peptide Therapeutics: Contract API Manufacturing Market by Scale of Operation (Preclinical / Clinical and Commercial), Type of Synthesis Method Used (Chemical Synthesis Method and Non-Chemical Synthesis Method),
Published: January 31, 2022
Roots Analysis
Content info: 294 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents
  • List of Tables

Title:
Peptide Therapeutics:
Contract API Manufacturing Market by Scale of Operation (Preclinical / Clinical and Commercial), Type of Synthesis Method Used (Chemical Synthesis Method and Non-Chemical Synthesis Method), Company Size (Small, Mid-sized and Large), and Key Geographical Regions (North America, Europe, Asia Pacific and Rest of the World): Industry Trends and Global Forecasts, 2022-2035.

Example Insights:

The growing interest of stakeholders is evident from the rise in partnership activity; in recent years, a considerable share of deals were inked for manufacturing and product/process development purposes.

Overview:

Over the years, the popularity of biologics has led to an evident shift in the focus of pharmaceutical companies, from traditional interventions towards more complex and advanced pharmacological interventions, such as peptide therapeutics. Since the discovery of insulin, the peptide therapeutics market has evolved significantly. Presently, over 80 peptide-based drugs are available in the market for the treatment of an array of diseases, including cancer, chronic pain, diabetes, HIV infection, multiple sclerosis and osteoporosis. Further, since 2017, more than 10 peptide-based drugs have been approved by the USFDA. Of these, LupkynisTM and Zegalogue® were recently approved in 2021, while ImcivreeTM, Victoza®, LUPRON DEPOT®, Zoladex®, Sandostatin® and Somatuline® received approval in 2020. In this context, 1,000+ clinical trials have been / are being conducted to evaluate the therapeutic viability and future potential of novel peptides across various phases of development. The increasing popularity of this class of drugs can be attributed to their high specificity, affinity, less drug-drug interactions, diverse biological and chemical activity (enabling the enhancement of their half-lives), proven pharmacological value and favorable safety profiles. Considering the various advantages offered by such drugs, the demand for peptide-based therapeutics is increasing at a considerable pace.

It is worth highlighting that the peptide synthesis and purification domain is fraught with several challenges, including complexities associated with synthesis of complex, long chain macromolecules, which is known to affect the product yield and purity. In order to mitigate the aforementioned challenges, several players engaged in this domain prefer to outsource their operations to peptide contract manufacturers. Currently, more than 60 contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) claim to offer services for the development, design, manufacturing and purification of peptides. Owing to the fact that a large number of peptide therapeutic developers are outsourcing various aspects of their business processes, several CMOs / CDMOs have become one-stop-shops to cater to the diverse needs of peptide therapeutics developers. Considering the ongoing innovation in production technologies, purification techniques, evolving pipeline and increasing demand for peptide-based drug candidates, we believe that developer companies are likely to continue relying on contract manufacturing service providers and the market is inclined to witness a steady growth in the coming decade.

As pharma companies resume full-scale operation after the COVID-19 outbreak, the demand for large-scale peptide therapeutics contract API manufacturing is expected to increase significantly. It is worth highlighting that a number of peptide-based COVID-19 vaccines are being developed by pharmaceutical companies which further accelerate the high demand for peptide manufacturing service providers in order to scale-up production of these novel therapeutics post their approval, in order to meet the global demand.

Scope of the Report:

The "Peptide Therapeutics: Contract API Manufacturing Market by Scale of Operation (Preclinical / Clinical and Commercial), Type of Synthesis Method Used (Chemical Synthesis Method and Non-Chemical Synthesis Method), Company Size (Small, Mid-sized and Large), and Key Geographical Regions (North America, Europe, Asia Pacific and Rest of the World): Industry Trends and Global Forecasts, 2022-2035" report features an extensive study of the current market landscape and future opportunities associated with the contract manufacturing of therapeutic peptides, over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Amongst other elements, the report includes:

  • A detailed overview of the current market landscape of companies offering peptide contract manufacturing services, along with information on several relevant parameters, such as year of establishment, company size, scale of operation (preclinical, clinical and commercial), geographical location of CMO, number and location of their respective facilities, type of peptide synthesis method used (chemical and non-chemical), types of peptide modification services offered, type of peptide purification technology used (HPLC / UPLC, Ion-Exchange Chromatography and Size-Exchange Chromatography) and regulatory accreditations / certifications received.
  • An insightful company competitiveness analysis of prominent peptide contract manufacturers, based on several relevant parameters, such as service strength (in terms of experience of the service provider), and capabilities related to contract manufacturing of peptides (such as type of product, type of service(s) offered, number of manufacturing facilities, scale of operation, type of synthesis method used, type of purification technique used, and type of peptide modification).
  • Elaborate profiles of key players (shortlisted on the basis of the company competitiveness analysis) engaged in this domain. Each profile features a brief overview of the company, along with information on year of establishment, number of employees, location of headquarters, key executives, details related to peptide contract manufacturing services offered, recent developments, and an informed future outlook.
  • An analysis on the recent developments within the peptide contract manufacturing industry, highlighting information on several partnerships and collaborations and facility expansions that have taken place in this domain, during the period 2016-2021.
  • An in-depth analysis of completed, ongoing, and planned clinical studies focused on peptide therapeutics, based on several relevant parameters, such as trial registration year, phase of development, current trial status, enrolled patient population, study design, leading industry players (in terms of number of trials conducted), study focus and key geographical regions.
  • A detailed analysis of peptide contract manufacturing service providers' capabilities in different regions, based on several relevant parameters, such as number of CMOs, number of clinical sites, number of clinical trials, number of patients enrolled, number of peptide manufacturing facilities, type of product, number of clinical / commercial manufacturing CMOs, demand for peptide therapeutics and installed capacity.
  • Informed estimates of the annual commercial and clinical demand for peptide therapeutics, based on several relevant parameters, such as target patient population, dosing frequency and dose strength.
  • An estimate of the overall, installed capacity for manufacturing peptides, based on data reported by industry stakeholders in the public domain; the analysis takes into consideration the distribution of available peptide production capacity across companies of different sizes (small, mid-sized, large and very large firms), scale of operation (clinical and commercial), and key geographical regions (North America, Europe, Asia Pacific).
  • An analysis highlighting potential strategic partners segregated based on the likelihood of entering into collaboration with peptide therapeutics developers. These players have been shortlisted based on several relevant parameters, such as pipeline strength, pipeline maturity, year of establishment and company size.
  • A qualitative analysis highlighting the various factors that need to be taken into consideration by peptide drug developers, while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
  • A region-wise, detailed analysis of the total cost of ownership for a peptide contract manufacturing service provider. It features an informed estimate of direct and indirect expenses taking into consideration 11 relevant parameters, over a span of 10 years.
  • A discussion on regulatory guidelines related to peptide manufacturing, highlighting the key differences across various geographies, including the US, Europe, Australia, China, India, Japan and South Korea. It also includes details related to the various challenges, related to regulatory scrutiny, faced by peptide manufacturers.
  • An insightful discussion on how the recent COVID-19 pandemic is likely to impact the peptide contract manufacturing market, along with information on the key initiatives undertaken by service providers to overcome the challenges faced due to the pandemic.
  • A discussion on industry affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the evolution of this field; it includes a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on industry dynamics.

One of the key objectives of the report was to estimate the existing market size and the future growth potential within the peptide contract manufacturing market, based on several relevant parameters, such as projected growth of overall peptide-based products market, cost of goods sold and direct manufacturing costs. We have developed an informed estimate of the likely evolution of the market in the short to mid-term and mid to long term, over the period 2022-2035. Additionally, the report features the likely distribution of the current and forecasted opportunity across [A] scale of operation (preclinical / clinical and commercial) [B] type of synthesis method used [C] company size (small, mid-sized and large), and [D] key geographical regions (North America, Europe, Asia Pacific and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's evolution.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered:

  • Who are the key players engaged in offering contract manufacturing services for peptide therapeutics?
  • What are the different partnerships and expansion initiatives undertaken by peptide therapeutics contract manufacturers in the recent past?
  • Which regions represent the current key contract manufacturing hubs for peptide therapeutics?
  • What is the current, installed capacity for contract manufacturing of peptides therapeutics?
  • What is the current, global demand for peptide therapeutics? How is the demand for such candidates likely to evolve in the foreseen future?
  • What percentage of the peptide therapeutics manufacturing operations are presently outsourced?
  • What factors should be taken into consideration while deciding whether the manufacturing operations for peptide therapeutics should be kept in-house or outsourced?
  • How is the current and future opportunity likely to be distributed across key market segments?

Chapter Outlines:

Chapter 2 is an executive summary of key insights captured in our research. It offers a high-level view on the current state of the peptide contract manufacturing market and its likely evolution in the short-mid-term and long term.

Chapter 3 provides a general introduction to peptides, including a brief overview of different peptide classes, popular methods used for peptide synthesis and modification. It also highlights the different peptide purification strategies that are available in the market. Further, it includes information on the various applications of peptides, along with a brief overview of contract manufacturing. It also provides a detailed discussion on the need for outsourcing peptide manufacturing operations and its key advantages.

Chapter 4 features a detailed discussion on the regulatory landscape related to peptide contract manufacturers across various geographies, such as the US, Europe, Australia, China, India, Japan and South Korea. It also includes details related to the various challenges, related to regulatory scrutiny, faced by peptide manufacturers.

Chapter 5 provides an overview of the current market landscape of companies offering peptide contract manufacturing services, along with information on several relevant parameters, such as year of establishment, company size, scale of operation (preclinical, clinical and commercial), geographical location of CMO, number and location of their respective facilities, type of peptide synthesis method used (chemical and non-chemical), types of peptide modification services offered, type of peptide purification technology used (HPLC / UPLC, Ion-Exchange Chromatography and Size-Exchange Chromatography), and regulatory accreditations / certifications received.

Chapter 6 features an insightful company competitiveness analysis of prominent peptide contract manufacturers, based on several relevant parameters, such as service strength (in terms of experience of the service provider), and capabilities related to contract manufacturing of peptides (such as type of product, type of service(s) offered, number of manufacturing facilities, scale of operation, type of synthesis method used, type of purification technique used, and type of peptide modification).

Chapter 7 features profiles of key players (shortlisted on the basis of the company competitiveness analysis) engaged in this domain. Each profile features a brief overview of the company, along with information on year of establishment, number of employees, location of headquarters, key executives, details related to peptide contract manufacturing services offered, recent developments, and an informed future outlook.

Chapter 8 presents an analysis of the recent developments within the peptide contract manufacturing industry, highlighting information on several partnerships and collaborations and facility expansions that have taken place in this domain, during the period 2016-2021.

Chapter 9 presents an in-depth analysis of completed, ongoing, and planned clinical studies focused on peptide therapeutics, based on several relevant parameters, such as trial registration year, phase of development, current trial status, enrolled patient population, study design, leading industry players (in terms of number of trials conducted), study focus and key geographical regions.

Chapter 10 presents a detailed analysis of peptide contract manufacturing service providers' capabilities in different regions, based on several relevant parameters, such as number of CMOs, number of clinical sites, number of clinical trials, number of patients enrolled, number of peptide manufacturing facilities, type of product, number of clinical / commercial manufacturing CMOs, demand for peptide therapeutics and installed capacity.

Chapter 11 features a detailed analysis of the annual commercial and clinical demand for peptide therapeutics, based on several relevant parameters, such as target patient population, dosing frequency and dose strength.

Chapter 12 features an analysis of the overall, installed capacity for manufacturing peptides, based on data reported by industry stakeholders in the public domain; the analysis takes into consideration the distribution of available peptide production capacity across companies of different sizes (small, mid-sized and large firms), scale of operation (clinical and commercial), and key geographical regions (North America, Europe, Asia Pacific).

Chapter 13 presents potential strategic partners segregated based on the likelihood of entering into collaboration with peptide therapeutics developers. These players have been shortlisted based on several relevant parameters, such as pipeline strength, pipeline maturity, year of establishment and company size.

Chapter 14 presents qualitative analysis highlighting the various factors that need to be taken into consideration by peptide drug developers, while deciding whether to manufacture their respective products in-house or engage the services of a CMO.

Chapter 15 features a detailed analysis of the total cost of ownership for a peptide contract manufacturing service provider. It features an informed estimate of direct and indirect expenses taking into consideration 11 relevant parameters, over a span of 10 years.

Chapter 16 presents a detailed market forecast analysis, highlighting the likely growth of the peptide contract manufacturing market till the year 2035. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] scale of operation (preclinical / clinical and commercial) [B] type of synthesis method used [C] company size (small, mid-sized and large), and [D] key geographical regions (North America, Europe, Asia Pacific and Rest of the World).

Chapter 17 presents an insightful discussion on how the recent COVID-19 pandemic is likely to impact the peptide contract manufacturing market, along with information on the key initiatives undertaken by service providers to overcome the challenges faced due to the pandemic.

Chapter 18 provides a detailed discussion on industry affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the evolution of this field; it includes a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on industry dynamics.

Chapter 19 is a summary of the entire report. It provides the key takeaways and presents our independent opinion of the peptide CMOs market, based on the research and analysis described in the previous chapters. It also provides a recap of some of the upcoming future trends, which, we believe, are likely to influence the growth of peptide CMOs.

Chapter 20 presents the insights generated from a detailed survey, wherein we invited multiple stakeholders involved in the peptide therapeutics contract manufacturing market.

Chapter 21 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 22 is an appendix that provides the list of companies and organizations mentioned in the report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

  • 2.1. Chapter Overview

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Overview of Peptides
    • 3.2.1. Structural Analysis of Peptides
    • 3.2.2. Classification of Peptides
    • 3.2.3. Peptide Synthesis
    • 3.2.4. Type of Peptide Modification
      • 3.2.4.1. N-terminal Modification
      • 3.2.4.2. Internal Modification
      • 3.2.4.3. C-terminal Modification
      • 3.2.4.4. Other Modifications
    • 3.2.5. Peptide Purification
      • 3.2.5.1. Key Guidelines for Peptide Purity
  • 3.3. Overview of Contract Manufacturing
    • 3.3.1. Need for Outsourcing Peptide Manufacturing Operations
    • 3.3.2. Key Considerations for Selecting a CMO Partner
    • 3.3.3. Advantages of Outsourcing Manufacturing Services
    • 3.3.4. Risks and Challenges Associated with Outsourcing Peptide Manufacturing Operations
  • 3.4. Future Perspectives

4. REGULATORY LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Regulatory Scenario: North America
    • 4.2.1. The US Scenario
      • 4.2.1.1. Overview
      • 4.2.1.2. General Guidelines
  • 4.3. Regulatory Scenario: Europe
    • 4.3.1. The European Scenario
      • 4.3.1.1. Overview
      • 4.3.1.2. General Guidelines
  • 4.4. Regulatory Scenario: Asia Pacific
    • 4.4.1. Overview
    • 4.4.2. Australian Scenario
      • 4.4.2.1. General Guidelines
    • 4.4.3. Chinese Scenario
      • 4.4.3.1. General Guidelines
    • 4.4.4. Indian Scenario
      • 4.4.4.1. General Guidelines
    • 4.4.5. Japanese Scenario
      • 4.4.5.1. General Guidelines
    • 4.4.6. South Korean Scenario
      • 4.4.6.1. General Guidelines
  • 4.5. Key Challenges Associated with Peptide Manufacturing

5. COMPETITIVE LANDSCAPE

  • 5.1 Chapter Overview
  • 5.2 Contract Peptide API Manufacturers: Overall Market Landscape
    • 5.2.1. Analysis by Year of Establishment
    • 5.2.2. Analysis by Company Size
    • 5.2.3. Analysis by Location of Headquarters
    • 5.2.4. Analysis by Location of Manufacturing Facility (Continent-wise)
    • 5.2.5. Analysis by Location of Manufacturing Facility (Country-wise)
    • 5.2.6. Analysis by Type of Product
    • 5.2.7. Analysis by Type of Service(s) Offered
    • 5.2.8. Analysis by Scale of Operation
    • 5.2.9. Analysis by Type of Peptide Synthesis Method Used
    • 5.2.10. Analysis by Type of Peptide Modification Services Offered
    • 5.2.11. Analysis by Type of Purification Technology Used
    • 5.2.12. Analysis by Regulatory Accreditations / Certifications Received
  • 5.3. List of Custom Peptide Manufacturers

6. COMPANY COMPETITIVENESS ANALYSIS

  • 6.1. Chapter Overview
  • 6.2. Key Parameters
  • 6.3. Methodology
  • 6.4. Company Competitiveness Analysis: Peptide Therapeutics Contract API Manufacturers
    • 6.4.1 Company Competitiveness: Small Companies
    • 6.4.2 Company Competitiveness: Mid-sized Companies
    • 6.4.3. Company Competitiveness: Large Companies

7. COMPANY PROFILES

  • 7.1 Chapter Overview
  • 7.2. Contract Peptide API Manufacturers Based in North America
    • 7.2.1. AmbioPharm
      • 7.2.1.1. Company Overview
      • 7.2.1.2. Service Portfolio
      • 7.2.1.3. Manufacturing Facilities and Capabilities
      • 7.2.1.4. Recent Development and Future Outlook
    • 7.2.2. CPC Scientific
      • 7.2.2.1. Company Overview
      • 7.2.2.2. Service Portfolio
      • 7.2.2.3. Manufacturing Facilities and Capabilities
      • 7.2.2.4. Recent Developments and Future Outlook
    • 7.2.3. Creative Peptides
      • 7.2.3.1. Company Overview
      • 7.2.3.2. Service Portfolio
      • 7.2.3.3. Manufacturing Facilities and Capabilities
      • 7.2.3.4. Recent Developments and Future Outlook
    • 7.2.4. CSBio
      • 7.2.4.1. Company Overview
      • 7.2.4.2. Service Portfolio
      • 7.2.4.3. Manufacturing Facilities and Capabilities
      • 7.2.4.4. Recent Developments and Future Outlook
  • 7.3. Contract Peptide API Manufacturers Based in Europe
    • 7.3.1. Bachem
      • 7.3.1.1. Recent Developments and Company Overview
      • 7.3.1.2. Service Portfolio
      • 7.3.1.3. Manufacturing Facilities and Capabilities
      • 7.3.1.4. Recent Developments and Future Outlook
    • 7.3.2. BCN Peptide
      • 7.3.2.1. Company Overview
      • 7.3.2.2. Service Portfolio
      • 7.3.2.3. Manufacturing Facilities and Capabilities
      • 7.3.2.4. Recent Developments and Future Outlook
    • 7.3.3. Corden Pharma
      • 7.3.3.1. Company Overview
      • 7.3.3.2. Service Portfolio
      • 7.3.3.3. Manufacturing Facilities and Capabilities
      • 7.3.3.4. Recent Developments and Future Outlook
    • 7.3.4. PolyPeptide
      • 7.3.4.1. Company Overview
      • 7.3.4.2. Service Portfolio
      • 7.3.4.3. Manufacturing Facilities and Capabilities
      • 7.3.4.4. Recent Developments and Future Outlook
    • 7.3.5. Senn Chemicals
      • 7.3.5.1. Company Overview
      • 7.3.5.2. Service Portfolio
      • 7.3.5.3. Manufacturing Facilities and Capabilities
      • 7.3.5.4. Recent Developments and Future Outlook
  • 7.4. Contract Peptide API Manufacturers Based in Asia Pacific
    • 7.4.1. Auspep
      • 7.4.1.1. Company Overview
      • 7.4.1.2. Service Portfolio
      • 7.4.1.3. Manufacturing Facilities and Capabilities
      • 7.4.1.4. Recent Developments and Future Outlook
    • 7.4.2. Chinese Peptide
      • 7.4.2.1. Company Overview
      • 7.4.2.2. Service Portfolio
      • 7.4.2.3. Manufacturing Facilities and Capabilities
      • 7.4.2.4. Recent Developments and Future Outlook
    • 7.4.3. Hybio Pharmaceutical
      • 7.4.3.1. Company Overview
      • 7.4.3.2. Service Portfolio
      • 7.4.3.3. Manufacturing Facilities and Capabilities
      • 7.4.3.4. Recent Developments and Future Outlook
    • 7.4.4. Peptide Institute
      • 7.4.4.1. Company Overview
      • 7.4.4.2. Service Portfolio
      • 7.4.4.3. Manufacturing Facilities and Capabilities
      • 7.4.4.4. Recent Developments and Future Outlook
    • 7.4.5. ScinoPharm
      • 7.4.5.1. Company Overview
      • 7.4.5.2. Service Portfolio
      • 7.4.5.3. Manufacturing Facilities and Capabilities
      • 7.4.5.4. Recent Developments and Future Outlook

8. RECENT DEVELOPMENTS

  • 8.1. Chapter Overview
  • 8.2. Partnerships Models
  • 8.3. Peptide Therapeutics Contract API Manufacturers: List of Partnerships and Collaborations
    • 8.3.1. Analysis by Year of Partnership
    • 8.3.2. Analysis by Type of Partnership
    • 8.3.3. Analysis by Scale of Operation
    • 8.3.4. Analysis by Region (Continent-wise)
      • 8.3.4.1. Analysis by Region (Country-wise)
      • 8.3.4.2. Intercontinental and Intracontinental Distribution
  • 8.4. Expansion Models
  • 8.5. List of Recent Expansions
    • 8.5.1. Analysis by Year of Expansion
    • 8.5.2. Analysis by Type of Expansion
    • 8.5.3. Analysis by Location of Expansion (Continent-wise)
    • 8.5.4. Analysis by Location of Expansion (Country-wise)
  • 8.6. Emerging Peptide Synthesis Technologies
    • 8.6.1. Chemo-Enzymatic Peptide Synthesis Technology
    • 8.6.2. Continuous Flow Technology
    • 8.6.3. Green Chemistry

9. CLINICAL TRIAL ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Scope and Methodology
  • 9.3. Peptide Therapeutics: List of Clinical Trials
    • 9.3.1. Analysis by Trial Status
    • 9.3.2. Analysis by Trial Registration Year
    • 9.3.3. Analysis by Type of Masking
    • 9.3.4. Analysis by Type of Intervention Model
    • 9.3.5. Analysis by Study Design
    • 9.3.6. Analysis by Phase of Development
    • 9.3.7. Analysis by Type of Sponsor
    • 9.3.8. Most Active Players: Analysis by Number of Trials Registered
    • 9.3.9. Analysis by Trial Registration Year and Trial Status
    • 9.3.10. Analysis by Trial Registration Year and Geography
    • 9.3.11. Analysis by Number of Trials, Trial Status and Geography
    • 9.3.12. Analysis by Number of Trials, Trial Registration Year and Geography
  • 9.4. Analysis of Enrolled Patient Population
    • 9.4.1. Analysis of Enrolled Patient Population by Geography
    • 9.4.2. Analysis by Number of Patients Enrolled, Trial Status and Geography
    • 9.4.3. Analysis by Phase of Development, Trial Registration Year and Number of Patients Enrolled
    • 9.4.4. Analysis of Number of Clinical Trials by Geography

10. REGIONAL CAPABILITY ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Key Assumptions and Methodology
  • 10.3. Overall Landscape of Contract Peptide API Manufacturers
  • 10.4. Contract Peptide API Manufacturers in North America
  • 10.5. Contract Peptide API Manufacturers in Europe
  • 10.6. Contract Peptide API Manufacturing in Asia Pacific

11. DEMAND ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Assumptions and Methodology
  • 11.3. Peptide API Manufacturing: Overall Annual Demand
    • 11.3.1. Analysis by Geography

12. CAPACITY ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Assumptions and Methodology
  • 12.3. Peptide API Manufacturing: Installed Global Capacity
    • 12.3.1. Analysis by Company Size
    • 12.3.2. Analysis by Scale of Operation
    • 12.3.3. Analysis by Location of Manufacturing Facility
    • 12.3.4. Analysis by Company Size and Location of Manufacturing Facility
    • 12.3.5. Analysis by Scape of Operation and Location of Manufacturing Facility
  • 12.4. Concluding Remarks

13. LIKELY PARTNERS FOR PEPTIDE THERAPEUTICS CONTRACT API MANUFACTURING SERVICE PROVIDERS

  • 13.1. Chapter Overview
  • 13.2. Scope and Methodology
  • 13.3. Potential Strategic Partners for Peptide Contract Manufacturers

14. MAKE VERSUS BUY DECISION MAKING FRAMEWORK

  • 14.1. Chapter Overview
  • 14.2. Assumptions and Parameter Definitions
    • 14.2.1. Scenario 1
    • 14.2.2. Scenario 2
    • 14.2.3. Scenario 3
    • 14.2.4. Scenario 4
  • 14.3. Concluding Remarks

15. TOTAL COST OF OWNERSHIP IN PEPTIDE CONTRACT MANUFACTURING ORGANIZATION

  • 15.1. Chapter Overview
  • 15.2. Expenditures Incurred by a Peptide Contract Manufacturing Organization
    • 15.2.1. Capital Expenditures (CAPEX)
    • 15.2.2. Operational Expenditures (OPEX)
  • 15.3. Assumptions and Methodology
  • 15.4. Total Cost of Ownership of Peptide Contract Manufacturing Organization, 2021-2030
  • 15.5. Total Cost of Ownership of Peptide Contract Manufacturing Organization: Distribution by CAPEX and OPEX, 2021-2030
    • 15.5.1. Total Cost of Ownership of Peptide Contract Manufacturing Organization: Distribution by CAPEX, 2021-2030
    • 15.5.2. Total Cost of Ownership of Peptide Contract Manufacturing Organization: Distribution by OPEX, 2021-2030
  • 15.6. Concluding Remarks

16. MARKET SIZING AND OPPORTUNITY ANALYSIS

  • 16.1. Chapter Overview
  • 16.2. Assumptions and Forecast Methodology
  • 16.3. Overall Peptide Therapeutics Contract Manufacturing Market, 2022-2035
    • 16.3.1. Peptide Therapeutics Contract API Manufacturing Market, 2022-2035
    • 16.3.2. Peptide Therapeutics Contract FDF Manufacturing Market, 2022-2035
  • 16.4. Peptide Therapeutics Contract API Manufacturing Market, 2022-2035: Distribution by Scale of Operation
  • 16.5. Peptide Therapeutics Contract API Manufacturing Market, 2022-2035: Distribution by Type of Peptide Synthesis Method Used
    • 16.5.1. Peptide Therapeutics Contract API Manufacturing Market, 2022-2035: Distribution by Type of Chemical Synthesis Method Used
  • 16.6. Peptide Therapeutics Contract API Manufacturing Market, 2022-2035: Distribution by Company Size
  • 16.7. Peptide Therapeutics Contract API Manufacturing Market, 2022-2035: Distribution by Key Geographical Regions
    • 16.7.1. Peptide Therapeutics Contract API Manufacturing Market in North America, 2022-2035
      • 16.7.1.1. Peptide Therapeutics Contract API Manufacturing Market in North America, 2022-2035: Share of Small Companies
      • 16.7.1.2. Peptide Therapeutics Contract API Manufacturing Market in North America, 2022-2035: Share of Mid-sized Companies
      • 16.7.1.3. Peptide Therapeutics Contract API Manufacturing Market in North America, 2022-2035: Share of Large Companies
      • 16.7.1.4. Peptide Therapeutics Contract API Manufacturing Market in North America, 2022-2035: Share of Preclinical / Clinical Scale Operations
      • 16.7.1.5. Peptide Therapeutics Contract API Manufacturing Market in North America, 2022-2035: Share of Commercial Scale Operations
      • 16.7.1.6. Peptide Therapeutics Contract API Manufacturing Market in North America, 2022-2035: Share of Chemical Synthesis Methods
      • 16.7.1.8. Peptide Therapeutics Contract API Manufacturing Market in North America, 2022-2035: Share of Non-Chemical Synthesis Methods
    • 16.7.2. Peptide Therapeutics Contract API Manufacturing Market in Europe, 2022-2035
      • 16.7.2.1. Peptide Therapeutics Contract API Manufacturing Market in Europe, 2022-2035: Share of Small Companies
      • 16.7.2.2. Peptide Therapeutics Contract API Manufacturing Market in Europe, 2022-2035: Share of Mid-sized Companies
      • 16.7.2.3. Peptide Therapeutics Contract API Manufacturing Market in Europe, 2022-2035: Share of Large Companies
      • 16.7.2.4. Peptide Therapeutics Contract API Manufacturing Market in Europe, 2022-2035: Share of Preclinical / Clinical Scale Operations
      • 16.7.2.5. Peptide Therapeutics Contract API Manufacturing Market in Europe, 2022-2035: Share of Commercial Scale Operations
      • 16.7.2.6. Peptide Therapeutics Contract API Manufacturing Market in Europe, 2022-2035: Share of Chemical Synthesis Methods
      • 16.7.2.8. Peptide Therapeutics Contract API Manufacturing Market in Europe, 2022-2035: Share of Non-Chemical Synthesis Methods
    • 16.7.3. Peptide Therapeutics Contract API Manufacturing Market in Asia Pacific, 2022-2035
      • 16.7.3.1. Peptide Therapeutics Contract API Manufacturing Market in Asia Pacific, 2022-2035: Share of Small Companies
      • 16.7.3.2. Peptide Therapeutics Contract API Manufacturing Market in Asia Pacific, 2022-2035: Share of Mid-sized Companies
      • 16.7.3.3. Peptide Therapeutics Contract API Manufacturing Market in Asia Pacific, 2022-2035: Share of Large Companies
      • 16.7.3.4. Peptide Therapeutics Contract API Manufacturing Market in Asia Pacific, 2022-2035: Share of Preclinical / Clinical Scale Operations
      • 16.7.3.5. Peptide Therapeutics Contract API Manufacturing Market in Asia Pacific, 2022-2035: Share of Commercial Scale Operations
      • 16.7.3.6. Peptide Therapeutics Contract API Manufacturing Market in Asia Pacific, 2022-2035: Share of Chemical Synthesis Methods
      • 16.7.3.7. Peptide Therapeutics Contract API Manufacturing Market in Asia Pacific, 2022-2035: Share of Non-Chemical Synthesis Methods

17. IMPACT OF THE COVID-19 PANDEMIC ON THE PEPTIDE API CONTRACT MANUFACTURING MARKET

  • 17.1. Chapter Overview
  • 17.2. Current Options and Recuperative Initiatives of Key Players
    • 17.2.1. Bachem
    • 17.2.2. CPC Scientific
    • 17.2.3. Corden Pharma
    • 17.2.4. PolyPeptide
    • 17.2.5. Wuxi AppTec
  • 17.3. Impact on Peptide API Contract Manufacturing Market

18. SWOT ANALYSIS

  • 18.1. Chapter Overview
  • 18.2. Strengths
  • 18.3. Weaknesses
  • 18.4. Opportunities
  • 18.5. Threats
  • 18.6. Comparison of SWOT Factors
  • 18.7. Concluding Remark

19. CONCLUSION

  • 19.1. Chapter Overview

20. SURVEY TRANSCRIPT(S)

21. APPENDIX 1: TABULATED DATA

22. APPENDIX 2: LIST OF COMPANIES AND ORGANISTIONS

List Of Figures

  • Figure 3.1. Peptide Synthesis Strategies
  • Figure 3.2. Peptide Modification Techniques
  • Figure 3.3. Types of Third-Party Service Providers
  • Figure 4.1. Regulatory Landscape: Peptide Classification in the US
  • Figure 5.1. Peptide Therapeutics Contract API Manufacturers: Distribution by Year of Establishment
  • Figure 5.2. Peptide Therapeutics Contract API Manufacturers: Distribution by Company Size
  • Figure 5.3. Peptide Therapeutics Contract API Manufacturers: Distribution by Location of Headquarters
  • Figure 5.4. Peptide Therapeutics Contract API Manufacturers: Distribution by Location of Manufacturing Facilities (Continent-wise)
  • Figure 5.5. Peptide Therapeutics Contract API Manufacturers: Distribution by Location of Manufacturing Facilities (Country-wise)
  • Figure 5.6. Peptide Therapeutics Contract API Manufacturers: Distribution by Type of Product
  • Figure 5.7. Peptide Therapeutics Contract API Manufacturers: Distribution by Type of Service(s) Offered
  • Figure 5.8. Peptide Therapeutics Contract API Manufacturers: Distribution by Scale of Operation
  • Figure 5.9. Peptide Therapeutics Contract API Manufacturers: Distribution by Type of Peptide Synthesis Method Used
  • Figure 5.10. Peptide Therapeutics Contract API Manufacturers: Distribution by Type of Peptide Modification Services Offered
  • Figure 5.11. Peptide Therapeutics Contract API Manufacturers: Distribution by Type of Purification Technology Used
  • Figure 5.12. Peptide Therapeutics Contract API Manufacturers: Distribution by Regulatory Accreditations / Certifications Received
  • Figure 6.1. Company Competitiveness Analysis: Dot-Plot Representation (Small Players)
  • Figure 6.2. Company Competitiveness Analysis: Dot-Plot Representation (Mid-sized Players)
  • Figure 6.3. Company Competitiveness Analysis: Dot-Plot Representation (Large Players)
  • Figure 7.1. AmbioPharm: Service Portfolio
  • Figure 7.2. CPC Scientific: Service Portfolio
  • Figure 7.3. Creative Peptides: Service Portfolio
  • Figure 7.4. CSBio: Service Portfolio
  • Figure 7.5. Bachem: Service Portfolio
  • Figure 7.6. BCN Peptide: Service Portfolio
  • Figure 7.7. Corden Pharma: Service Portfolio
  • Figure 7.8. PolyPeptide: Service Portfolio
  • Figure 7.9. Senn Chemical: Service Portfolio
  • Figure 7.10. Auspep: Service Portfolio
  • Figure 7.11. Chinese Peptide: Service Portfolio
  • Figure 7.12. Hybio Pharmaceuticals: Service Portfolio
  • Figure 7.13. Peptide Institute: Service Portfolio
  • Figure 7.14. ScinoPharm: Service Portfolio
  • Figure 8.1. Partnerships and Collaborations: Distribution by Year of Partnership
  • Figure 8.2. Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 8.3. Partnerships and Collaborations: Distribution by Scale of Operation
  • Figure 8.4. Partnerships and Collaborations: Distribution by Region (Continent-wise)
  • Figure 8.5. Partnerships and Collaborations: Distribution by Region (Country-wise)
  • Figure 8.6. Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
  • Figure 8.7. Recent Expansions: Distribution by Year of Expansion
  • Figure 8.8. Recent Expansions: Distribution by Type of Expansion
  • Figure 8.9. Recent Expansions: Distribution by Location of Expansion (Continent-Wise)
  • Figure 8.10. Recent Expansions: Distribution by Location of Expansion (Country-Wise)
  • Figure 8.11. Chemo-Enzymatic Peptide Synthesis Technology: Advantages and Disadvantages
  • Figure 8.12. Continuous Flow Technology: Advantages and Disadvantages
  • Figure 8.13. Green Chemistry: Advantages and Disadvantages
  • Figure 9.1. Clinical Trial Analysis: Distribution by Trial Status
  • Figure 9.2. Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year
  • Figure 9.3. Clinical Trial Analysis: Distribution by Type of Masking
  • Figure 9.4. Clinical Trial Analysis: Distribution by Intervention Model Adopted
  • Figure 9.5. Clinical Trial Analysis: Distribution by Study Design
  • Figure 9.6. Clinical Trial Analysis: Distribution by Phase of Development
  • Figure 9.7. Clinical Trial Analysis: Distribution by Type of Sponsor
  • Figure 9.8. Most Active Players: Distribution by Number of Clinical Trials
  • Figure 9.9. Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
  • Figure 9.10. Clinical Trial Analysis: Distribution by Trial Registration Year and Geography
  • Figure 9.11. Clinical Trial Analysis: Distribution by Number of Trials, Trial Status and Geography
  • Figure 9.12. Clinical Trial Analysis: Distribution by Number of Trials, Trial Registration Year and Geography
  • Figure 9.13. Clinical Trial Analysis: Distribution by Enrolled Patient Population
  • Figure 9.14. Clinical Trial Analysis: Distribution of Enrolled Patients Population by Geography
  • Figure 9.15. Clinical Trial Analysis: Distribution by Number of Patients Enrolled, Trial Status and Geography
  • Figure 9.16. Clinical Trial Analysis: Distribution by Phase of Development, Trial Registration Year and Number of Patients Enrolled
  • Figure 9.17. Clinical Trial Analysis: Distribution of Number of Clinical Trials by Geography
  • Figure 10.1. Regional Capability Analysis: Distribution by Location of Manufacturing Facilities
  • Figure 10.2. Regional Capability Analysis: North America
  • Figure 10.3. Regional Capability Analysis: Europe
  • Figure 10.4. Regional Capability Analysis: Asia Pacific
  • Figure 11.1. Demand Analysis: Annual Demand for Peptide Therapeutics (in Kilograms)
  • Figure 11.2. Demand Analysis: Distribution by Geographical Location
  • Figure 12.1. Peptide Therapeutics Contract API Manufacturing Installed Global Capacity: Distribution by Company Size
  • Figure 12.2. Peptide Therapeutics Contract API Manufacturing Installed Global Capacity: Distribution by Range of Installed Capacity
  • Figure 12.3. Peptide Therapeutics Contract API Manufacturing Installed Global Capacity: Distribution by Scale of Operation
  • Figure 12.4. Peptide Therapeutics Contract API Manufacturing Installed Global Capacity: Distribution by Location of Manufacturing Facility
  • Figure 12.5. Peptide Therapeutics Contract API Manufacturing Installed Global Capacity: Distribution by Company Size and Location of Manufacturing Facility
  • Figure 12.6. Peptide Therapeutics Contract API Manufacturing Installed Global Capacity: Distribution by Scale of Operation and Location of Manufacturing Facility
  • Figure 14.1. Make versus Buy Decision Making Framework
  • Figure 14.2. Make versus Buy Decision Making: Possible Scenario Descriptions
  • Figure 15.1 Total Cost of Ownership: Capital Expenditures (CAPEX)
  • Figure 15.2 Total Cost of Ownership: Operational Expenditures (OPEX)
  • Figure 15.3 Total Cost of Ownership: Other Costs
  • Figure 15.4 Total Cost of ownership in Peptide Therapeutics Contract API Manufacturing Organization, 2021-2030 (USD Million)
  • Figure 15.5 Total Cost of Ownership in Peptide Therapeutics Contract API Manufacturing Organization: Distribution by CAPEX and OPEX, 2021-2030 (USD Million)
  • Figure 15.6 Total Cost of Ownership in Peptide Therapeutics Contract API Manufacturing Organization, 2021-2030: Distribution by CAPEX (USD Million)
  • Figure 15.7 Total Cost of Ownership in Peptide Therapeutics Contract API Manufacturing Organization, 2021-2030: Distribution by OPEX (USD Million)
  • Figure 16.1. Overall Peptide Therapeutics Contract Manufacturing Market, 2022-2035 (USD Billion)
  • Figure 16.2. Peptide Therapeutics Contract API Manufacturing Market, 2022-2035 (USD Billion)
  • Figure 16.3. Peptide Therapeutics Contract FDF Manufacturing Market, 2022-2035 (USD Billion)
  • Figure 16.4. Peptide Therapeutics Contract API Manufacturing Market: Distribution by Scale of Operation, 2022-2035 (USD Million)
  • Figure 16.5. Peptide Therapeutics Contract API Manufacturing Market: Distribution by Type of Peptide Synthesis Method Used, 2022-2035 (USD Billion)
  • Figure 16.6. Peptide Therapeutics Contract API Manufacturing Market: Distribution by Type of Peptide Chemical Synthesis Methods Used, 2022-2035 (USD Billion)
  • Figure 16.7. Peptide Therapeutics Contract API Manufacturing Market: Distribution by Type of Peptide Synthesis Methods Used, 2028 and 2035
  • Figure 16.8. Peptide Therapeutics Contract API Manufacturing Market: Distribution by Company Size, 2022-2035 (USD Million)
  • Figure 16.9. Peptide Therapeutics Contract API Manufacturing Market: Distribution by Key Geographical Regions, 2022, 2028 and 2035 (USD Billion)
  • Figure 16.10. Peptide Therapeutics Contract API Manufacturing Market in North America, 2022-2035 (USD Billion)
  • Figure 16.11. Peptide Therapeutics Contract API Manufacturing Market in North America, 2022-2035: Share of Small Companies (USD Billion)
  • Figure 16.12. Peptide Therapeutics Contract API Manufacturing Market in North America, 2022-2035: Share of Mid-sized Companies (USD Billion)
  • Figure 16.13. Peptide Therapeutics Contract API Manufacturing Market in North America, 2022-2035: Share of Large Companies (USD Billion)
  • Figure 16.14. Peptide Therapeutics Contract API Manufacturing Market in North America, 2022-2035: Share of Preclinical / Clinical Operations (USD Billion)
  • Figure 16.15. Peptide Therapeutics Contract API Manufacturing Market in North America, 2022-2035: Share of Commercial Operations (USD Billion)
  • Figure 16.16. Peptide Therapeutics Contract API Manufacturing Market in North America, 2022-2035: Share of Chemical Synthesis Method (USD Million)
  • Figure 16.17. Peptide Therapeutics Contract API Manufacturing Market in North America, 2022-2035: Share of Non-Chemical Synthesis Method (USD Million)
  • Figure 16.18. Peptide Therapeutics Contract API Manufacturing Market in Europe, 2022-2035 (USD Million)
  • Figure 16.19. Peptide Therapeutics Contract API Manufacturing Market in Europe, 2022-2035: Share of Small Companies (USD Million)
  • Figure 16.20. Peptide Therapeutics Contract API Manufacturing Market in Europe, 2022-2035: Share of Mid-sized Companies (USD Million)
  • Figure 16.21. Peptide Therapeutics Contract API Manufacturing Market in Europe, 2022-2035: Share of Large Companies (USD Million)
  • Figure 16.22. Peptide Therapeutics Contract API Manufacturing Market in Europe, 2022-2035: Share of Preclinical / Clinical Operations (USD Million)
  • Figure 16.23. Peptide Therapeutics Contract API Manufacturing Market in Europe, 2022-2035: Share of Commercial Operations (USD Million)
  • Figure 16.24. Peptide Therapeutics Contract API Manufacturing Market in Europe, 2022-2035: Share of Chemical Synthesis Method (USD Million)
  • Figure 16.25. Peptide Therapeutics Contract API Manufacturing Market in Europe, 2022-2035: Share of Non-Chemical Synthesis Method (USD Million)
  • Figure 16.26. Peptide Therapeutics Contract API Manufacturing Market in Asia Pacific and RoW, 2022-2035 (USD Million)
  • Figure 16.27. Peptide Therapeutics Contract API Manufacturing Market in Asia Pacific and RoW, 2022-2035: Share of Small Companies (USD Million)
  • Figure 16.28. Peptide Therapeutics Contract API Manufacturing Market in Asia Pacific and RoW, 2022-2035: Share of Mid-sized Companies (USD Million)
  • Figure 16.29. Peptide Therapeutics Contract API Manufacturing Market in Asia Pacific and RoW, 2022-2035: Share of Large Companies (USD Million)
  • Figure 16.30. Peptide Therapeutics Contract API Manufacturing Market in Asia Pacific and RoW, 2022-2035: Share of Preclinical / Clinical Operations (USD Million)
  • Figure 16.31. Peptide Therapeutics Contract API Manufacturing Market in Asia Pacific and RoW, 2022-2035: Share of Commercial Operations (USD Million)
  • Figure 16.32. Peptide Therapeutics Contract API Manufacturing Market in Asia Pacific and RoW, 2022-2035: Share of Chemical Synthesis Method (USD Million)
  • Figure 16.33. Peptide Therapeutics Contract API Manufacturing Market in Asia Pacific and RoW, 2022-2035: Share of Non-Chemical Synthesis Method (USD Million)
  • Figure 17.1. Peptide Therapeutics Contract API Manufacturing Services Market, 2016-2031: COVID-19 Impact Scenario (USD Billion)
  • Figure 18.1. Contract Peptide API Manufacturing: SWOT Analysis
  • Figure 18.2. Comparison of SWOT Factors: Harvey Ball Analysis

List Of Tables

  • Table 3.1. Comparison of Major Peptide Synthesizing Processes
  • Table 3.2. Chromatographic Techniques
  • Table 5.1. List of Contract Peptide API Manufacturers
  • Table 5.2. Peptide Therapeutics Contract API Manufacturers: Information on Type of Product
  • Table 5.3. Peptide Therapeutics Contract API Manufacturers: Information on Type of Service(s) Offered
  • Table 5.4. Peptide Therapeutics Contract API Manufacturers: Information on Scale of Operation
  • Table 5.5. Peptide Therapeutics Contract API Manufacturers: Information on Type of Peptide Synthesis Method Used
  • Table 5.6. Peptide Therapeutics Contract API Manufacturers: Information on Type of Peptide Modification Service Offered
  • Table 5.7. Peptide Therapeutics Contract API Manufacturers: Information on Type of Purification Technology Used
  • Table 5.8. Peptide Therapeutics Contract API Manufacturers: Information on Regulatory Accreditations / Certifications Received
  • Table 5.9. List of Custom Peptide Manufacturers
  • Table 6.1 Company Competitiveness Analysis: Small Companies
  • Table 6.2 Company Competitiveness Analysis: Mid-sized Companies
  • Table 6.3 Company Competitiveness Analysis: Large Companies
  • Table 7.1. AmbioPharm: Company Overview
  • Table 7.2. AmbioPharm: Overview of Manufacturing Capabilities
  • Table 7.3. AmbioPharm: Recent Developments and Future Outlook
  • Table 7.4. CPC Scientific: Company Overview
  • Table 7.5. CPC Scientific: Overview of Manufacturing Capabilities
  • Table 7.6. Creative Peptides: Company Overview
  • Table 7.7. Creative Peptides: Overview of Manufacturing Capabilities
  • Table 7.8. CSBio: Company Overview
  • Table 7.9. CSBio: Overview of Manufacturing Capabilities
  • Table 7.10. Bachem: Company Overview
  • Table 7.11. Bachem: Overview of Manufacturing Capabilities
  • Table 7.12. BCN Peptide: Company Overview
  • Table 7.13. BCN Peptide: Overview of Manufacturing Capabilities
  • Table 7.14. Corden Pharma: Company Overview
  • Table 7.15. Corden Pharma: Overview of Manufacturing Capabilities
  • Table 7.16. Corden Pharma: Recent Developments and Future Outlook
  • Table 7.17. PolyPeptide: Company Overview
  • Table 7.18. PolyPeptide: Overview of Manufacturing Capabilities
  • Table 7.19. Senn Chemicals: Company Overview
  • Table 7.20. Senn Chemicals: Overview of Manufacturing Capabilities
  • Table 7.21. Auspep: Company Overview
  • Table 7.22. Auspep: Overview of Manufacturing Capabilities
  • Table 7.23. Chinese Peptide: Company Overview
  • Table 7.24. Chinese Peptide: Overview of Manufacturing Capabilities
  • Table 7.25. Hybio Pharmaceuticals: Company Overview
  • Table 7.26. Hybio Pharmaceuticals: Overview of Manufacturing Capabilities
  • Table 7.27. Peptide Institute: Company Overview
  • Table 7.28. Peptide Institute: Overview of Manufacturing Capabilities
  • Table 7.29. ScinoPharm: Company Overview
  • Table 7.30. ScinoPharm: Overview of Manufacturing Capabilities
  • Table 8.1. Contract Peptide API Manufacturers: List of Recent Partnerships, 2016-2021
  • Table 8.2. Contract Peptide API Manufacturers: List of Recent Expansions, 2016-2021
  • Table 9.1. Peptide Therapeutics: List of Clinical Trials
  • Table 12.1. Capacity Analysis: Average Capacity for Peptide Synthesis (Dataset)
  • Table 12.2. Capacity Analysis: List of Companies with Installed Capacity
  • Table 12.3. Capacity Analysis: Installed Global Capacity
  • Table 13.1. Industry Players in North America: Most Likely Partners
  • Table 13.2. Industry Players in North America: Likely Partners
  • Table 13.3. Industry Players in North America: Less Likely Partners
  • Table 13.4. Non-Industry Players in North America: Most Likely Partners
  • Table 13.5. Non-Industry Players in North America: Likely Partners
  • Table 13.6. Non-Industry Players in North America: Less Likely Partners
  • Table 13.7. Industry Players in Europe: Most Likely Partners
  • Table 13.8. Industry Players in Europe: Likely Partners
  • Table 13.9. Industry Players in Europe: Less Likely Partners
  • Table 13.10. Non-Industry Players in Europe: Most Likely Partners
  • Table 13.11. Non-Industry Players in Europe: Likely Partners
  • Table 13.12. Non-Industry Players in Europe: Less Likely Partners
  • Table 13.13. Industry Players in Asia-Pacific: Most Likely Partners
  • Table 13.14. Industry Players in Asia-Pacific: Likely Partners
  • Table 13.15. Industry Players in Asia-Pacific: Less Likely Partners
  • Table 13.16. Non-Industry Players in Asia-Pacific: Most Likely Partners
  • Table 13.17. Non-Industry Players in Asia-Pacific: Likely Partners
  • Table 13.18. Non-Industry Players in Asia-Pacific: Less Likely Partners
  • Table 19.1. Peptide Therapeutics Contract API Manufacturing Market: Key Takeaways
  • Table 21.1. Peptide Therapeutics Contract API Manufacturers: Distribution by Year of Establishment
  • Table 21.2. Peptide Therapeutics Contract API Manufacturers: Distribution by Company Size
  • Table 21.3. Peptide Therapeutics Contract API Manufacturers: Distribution by Location of Headquarters
  • Table 21.4. Peptide Therapeutics Contract API Manufacturers: Distribution by Location of Manufacturing Facilities (Continent-wise)
  • Table 21.5. Peptide Therapeutics Contract API Manufacturers: Distribution by Location of Manufacturing Facilities (Country-wise)
  • Table 21.6. Peptide Therapeutics Contract API Manufacturers: Distribution by Type of Product
  • Table 21.7. Peptide Therapeutics Contract API Manufacturers: Distribution by Type of Service(s) Offered
  • Table 21.8. Peptide Therapeutics Contract API Manufacturers: Distribution by Scale of Operation
  • Table 21.9. Peptide Therapeutics Contract API Manufacturers: Distribution by Type of Peptide Synthesis Method Used
  • Table 21.10. Peptide Therapeutics Contract API Manufacturers: Distribution by Type of Peptide Modification Services Offered
  • Table 21.11. Peptide Therapeutics Contract API Manufacturers: Distribution by Type of Purification Technology Used
  • Table 21.12. Peptide Therapeutics Contract API Manufacturers: Distribution by Regulatory Accreditations / Certifications Received
  • Table 21.13. Company Competitiveness Analysis: Dot-Plot Representation (Small Players)
  • Table 21.14. Company Competitiveness Analysis: Dot-Plot Representation (Mid-sized Players)
  • Table 21.15. Company Competitiveness Analysis: Dot-Plot Representation (Large Players)
  • Table 21.16. Partnerships and Collaborations: Distribution by Year of Partnership
  • Table 21.17. Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 21.18. Partnerships and Collaborations: Distribution by Scale of Operation
  • Table 21.19. Partnerships and Collaborations: Distribution by Region (Continent-wise)
  • Table 21.20. Partnerships and Collaborations: Distribution by Region (Country-wise)
  • Table 21.21. Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
  • Table 21.22. Recent Expansions: Distribution by Year of Expansion
  • Table 21.23. Recent Expansions: Distribution by Type of Expansion
  • Table 21.24. Recent Expansions: Distribution by Location of Expansion (Continent-Wise)
  • Table 21.25. Recent Expansions: Distribution by Location of Expansion (Country-Wise)
  • Table 21.26. Clinical Trial Analysis: Distribution by Trial Status
  • Table 21.27. Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year
  • Table 21.28. Clinical Trial Analysis: Distribution by Type of Masking
  • Table 21.29. Clinical Trial Analysis: Distribution by Intervention Model Adopted
  • Table 21.30. Clinical Trial Analysis: Distribution by Study Design
  • Table 21.31. Clinical Trial Analysis: Distribution by Phase of Development
  • Table 21.32. Clinical Trial Analysis: Distribution by Type of Sponsor
  • Table 21.33. Most Active Players: Distribution by Number of Clinical Trials
  • Table 21.34. Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
  • Table 21.35. Clinical Trial Analysis: Distribution by Trial Registration Year and Geography
  • Table 21.36. Clinical Trial Analysis: Distribution by Number of Trials, Trial Status and Geography
  • Table 21.37. Clinical Trial Analysis: Distribution by Number of Trials, Trial Registration Year and Geography
  • Table 21.38. Clinical Trial Analysis: Distribution by Enrolled Patient Population
  • Table 21.39. Clinical Trial Analysis: Distribution of Enrolled Patients Population by Geography
  • Table 21.40. Clinical Trial Analysis: Distribution by Number of Patients Enrolled, Trial Status and Geography
  • Table 21.41. Clinical Trial Analysis: Distribution by Phase of Development, Trial Registration Year and Number of Patients Enrolled
  • Table 21.42. Clinical Trial Analysis: Distribution of Number of Clinical Trials by Geography
  • Table 21.43. Regional Capability Analysis: Distribution by Location of Manufacturing Facilities
  • Table 21.44. Regional Capability Analysis: North America
  • Table 21.45. Regional Capability Analysis: Europe
  • Table 21.46. Regional Capability Analysis: Asia Pacific
  • Table 21.47. Demand Analysis: Annual Demand for Peptide Therapeutics (in Kilograms)
  • Table 21.48. Demand Analysis: Distribution by Geographical Location
  • Table 21.49. Peptide Therapeutics Contract API Manufacturing Installed Global Capacity: Distribution by Company Size
  • Table 21.50. Peptide Therapeutics Contract API Manufacturing Installed Global Capacity: Distribution by Range of Installed Capacity
  • Table 21.51. Peptide Therapeutics Contract API Manufacturing Installed Global Capacity: Distribution by Scale of Operation
  • Table 21.52. Peptide Therapeutics Contract API Manufacturing Installed Global Capacity: Distribution by Location of Manufacturing Facility
  • Table 21.53. Peptide Therapeutics Contract API Manufacturing Installed Global Capacity: Distribution by Company Size and Location of Manufacturing Facility
  • Table 21.54. Peptide Therapeutics Contract API Manufacturing Installed Global Capacity: Distribution by Scale of Operation and Location of Manufacturing Facility
  • Table 21.55. Total Cost of Ownership: Capital Expenditures (CAPEX)
  • Table 21.56. Total Cost of Ownership: Operational Expenditures (OPEX)
  • Table 21.57. Total Cost of Ownership: Other Costs
  • Table 21.58. Total Cost of ownership in Peptide Therapeutics Contract API Manufacturing Organization, 2021-2030 (USD Million)
  • Table 21.59. Total Cost of Ownership in Peptide Therapeutics Contract API Manufacturing Organization: Distribution by CAPEX and OPEX, 2022-2030 (USD Million)
  • Table 21.60. Total Cost of Ownership in Peptide Therapeutics Contract API Manufacturing Organization, 2022-2030: Distribution by CAPEX (USD Million)
  • Table 21.61. Total Cost of Ownership in Peptide Therapeutics Contract API Manufacturing Organization, 2022-2030: Distribution by OPEX (USD Million)
  • Table 21.62. Overall Peptide Therapeutics Contract Manufacturing Market, 2022-2035 (USD Billion)
  • Table 21.63. Peptide Therapeutics Contract API Manufacturing Market, 2022-2035 (USD Billion)
  • Table 21.64. Peptide Therapeutics Contract FDF Manufacturing Market, 2022-2035 (USD Billion)
  • Table 21.65. Peptide Therapeutics Contract API Manufacturing Market: Distribution by Scale of Operation, 2022-2035 (USD Million)
  • Table 21.66. Peptide Therapeutics Contract API Manufacturing Market: Distribution by Type of Peptide Synthesis Method Used, 2022-2035 (USD Billion)
  • Table 21.67. Peptide Therapeutics Contract API Manufacturing Market: Distribution by Type of Peptide Chemical Synthesis Methods Used, 2022-2035 (USD Billion)
  • Table 21.68. Peptide Therapeutics Contract API Manufacturing Market: Distribution by Type of Peptide Synthesis Methods Used, 2028 and 2035
  • Table 21.69. Peptide Therapeutics Contract API Manufacturing Market: Distribution by Company Size, 2022-2035 (USD Million)
  • Table 21.70. Peptide Therapeutics Contract API Manufacturing Market: Distribution by Key Geographical Regions, 2022, 2028 and 2035 (USD Billion)
  • Table 21.71. Peptide Therapeutics Contract API Manufacturing Market in North America, 2022-2035 (USD Billion)
  • Table 21.72. Peptide Therapeutics Contract API Manufacturing Market in North America, 2022-2035: Share of Small Companies (USD Billion)
  • Table 21.73. Peptide Therapeutics Contract API Manufacturing Market in North America, 2022-2035: Share of Mid-sized Companies (USD Billion)
  • Table 21.74. Peptide Therapeutics Contract API Manufacturing Market in North America, 2022-2035: Share of Large Companies (USD Billion)
  • Table 21.75. Peptide Therapeutics Contract API Manufacturing Market in North America, 2022-2035: Share of Preclinical / Clinical Operations (USD Billion)
  • Table 21.76. Peptide Therapeutics Contract API Manufacturing Market in North America, 2022-2035: Share of Commercial Operations (USD Billion)
  • Table 21.77. Peptide Therapeutics Contract API Manufacturing Market in North America, 2022-2035: Share of Chemical Synthesis Method (USD Million)
  • Table 21.78. Peptide Therapeutics Contract API Manufacturing Market in North America, 2022-2035: Share of Non-Chemical Synthesis Method (USD Million)
  • Table 21.79. Peptide Therapeutics Contract API Manufacturing Market in Europe, 2022-2035 (USD Million)
  • Table 21.80. Peptide Therapeutics Contract API Manufacturing Market in Europe, 2022-2035: Share of Small Companies (USD Million)
  • Table 21.81. Peptide Therapeutics Contract API Manufacturing Market in Europe, 2022-2035: Share of Mid-sized Companies (USD Million)
  • Table 21.82. Peptide Therapeutics Contract API Manufacturing Market in Europe, 2022-2035: Share of Large Companies (USD Million)
  • Table 21.83. Peptide Therapeutics Contract API Manufacturing Market in Europe, 2022-2035: Share of Preclinical / Clinical Operations (USD Million)
  • Table 21.84. Peptide Therapeutics Contract API Manufacturing Market in Europe, 2022-2035: Share of Commercial Operations (USD Million)
  • Table 21.85. Peptide Therapeutics Contract API Manufacturing Market in Europe, 2022-2035: Share of Chemical Synthesis Method (USD Million)
  • Table 21.86. Peptide Therapeutics Contract API Manufacturing Market in Europe, 2022-2035: Share of Non-Chemical Synthesis Method (USD Million)
  • Table 21.87. Peptide Therapeutics Contract API Manufacturing Market in Asia Pacific and RoW, 2022-2035 (USD Million)
  • Table 21.88. Peptide Therapeutics Contract API Manufacturing Market in Asia Pacific and RoW, 2022-2035: Share of Small Companies (USD Million)
  • Table 21.89. Peptide Therapeutics Contract API Manufacturing Market in Asia Pacific and RoW, 2022-2035: Share of Mid-sized Companies (USD Million)
  • Table 21.90. Peptide Therapeutics Contract API Manufacturing Market in Asia Pacific and RoW, 2022-2035: Share of Large Companies (USD Million)
  • Table 21.91. Peptide Therapeutics Contract API Manufacturing Market in Asia Pacific and RoW, 2022-2035: Share of Preclinical / Clinical Operations (USD Million)
  • Table 21.92. Peptide Therapeutics Contract API Manufacturing Market in Asia Pacific and RoW, 2022-2035: Share of Commercial Operations (USD Million)
  • Table 21.92. Peptide Therapeutics Contract API Manufacturing Market in Asia Pacific and RoW, 2022-2035: Share of Chemical Synthesis Method (USD Million)
  • Table 21.94. Peptide Therapeutics Contract API Manufacturing Market in Asia Pacific and RoW, 2022-2035: Share of Non-Chemical Synthesis Method (USD Million)
  • Table 21.95. Peptide Therapeutics Contract API Manufacturing Services Market, 2016-2031: COVID-19 Impact Scenario (USD Billion)

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  • 1. 13therapeutics
  • 2. 9 Meters Biopharma
  • 3. AAPPTec
  • 4. Abbiotec
  • 5. Abcepta
  • 6. Abclonal
  • 7. ABI Scientific
  • 8. Abzena
  • 9. ACES Pharma
  • 10. Activotec
  • 11. Adalvo
  • 12. Adar Biotech
  • 13. Advanced Accelerator Applications
  • 14. Advanced ChemTech
  • 15. Advanced Peptides
  • 16. Aileron Therapeutics
  • 17. Ajinomoto Bio-Pharma
  • 18. Akashi Therapeutics
  • 19. Albiochem
  • 20. Allysta Pharmaceuticals
  • 21. Almac
  • 22. Alpha Diagnostic
  • 23. AltaBioscience
  • 24. Altimmune
  • 25. AmbioPharm
  • 26. American Peptide Company
  • 27. Amgen
  • 28. AminoPrimeCentral
  • 29. Amolyt Pharma
  • 30. Ampio Pharmaceuticals
  • 31. Amunix
  • 32. Amyndas Pharmaceuticals
  • 33. Anaspec
  • 34. AnGes
  • 35. Anji Pharmaceuticals
  • 36. Antagene
  • 37. APAC Pharmaceutical
  • 38. Apellis Pharmaceuticals
  • 39. Apeptico
  • 40. APIM Therapeutics
  • 41. Apitope
  • 42. APL
  • 43. Aquestive Therapeutics
  • 44. Arch Biopartners
  • 45. Ardena
  • 46. Ascendia
  • 47. AsclepiX Therapeutics
  • 48. Aspen Oss
  • 49. AstraZeneca
  • 50. Asymchem
  • 51. Atlantic Peptides
  • 52. Atox Bio
  • 53. Aurigene Pharmaceutical Services
  • 54. Aurinia Pharmaceuticals
  • 55. Auspep
  • 56. Austin Chemical
  • 57. Averica
  • 58. Avilex Pharma
  • 59. Axon Neuroscience
  • 60. Baccinex
  • 61. Bachem
  • 62. BAM Biotech
  • 63. Bayer
  • 64. BCN Peptides
  • 65. Bicycle Therapeutics
  • 66. Bioassay
  • 67. BioConcept
  • 68. BioLineRx
  • 69. Biolingus
  • 70. Biomarck Pharmaceuticals
  • 71. BioMarin Pharmaceutical
  • 72. Biomer Technology
  • 73. Biopeptek Pharmaceuticals
  • 74. BioServ
  • 75. Bio-Synthesis
  • 76. BioVectra
  • 77. Boehringer Ingelheim
  • 78. Boston Therapeutics
  • 79. Burrard Pharmaceuticals
  • 80. California Peptide
  • 81. Cambridge Peptides
  • 82. Cambridge Research Biochemicals
  • 83. CanBas
  • 84. CanPeptide
  • 85. Capsugel
  • 86. Cara Therapeutics
  • 87. CARBOGEN AMCIS
  • 88. Carmot Therapeutics
  • 89. CASLO
  • 90. CBL
  • 91. Celtek Peptides
  • 92. CEM
  • 93. Cend Therapeutics
  • 94. Centre for Process Systems Engineering (CPSE)
  • 95. CHEMI
  • 96. ChemPartner
  • 97. ChemPep
  • 98. Chiasma Pharma
  • 99. ChinaTech Peptide
  • 100. Chinese Peptide Company
  • 101. Chondropeptix
  • 102. Chrysalis BioTherapeutics
  • 103. Clinuvel Pharmaceuticals
  • 104. CohBar
  • 105. Constant Therapeutics
  • 106. CordenPharma
  • 107. Corvid Pharmaceuticals
  • 108. Covalab
  • 109. CPC Scientific
  • 110. Creative Peptides
  • 111. CreoSalus
  • 112. CSBio
  • 113. CureDM
  • 114. Curia
  • 115. Curonz
  • 116. Cytovation
  • 117. Dalton Pharma
  • 118. Deca Peptide
  • 119. Designer Bioscience
  • 120. Diabetology
  • 121. Diapin Therapeutics
  • 122. Dottikon ES
  • 123. Eli Lilly
  • 124. Entera Bio
  • 125. Enteris BioPharma
  • 126. Enzene Biosciences
  • 127. Enzo Life Sciences
  • 128. EOC Pharma
  • 129. Esperance Pharmaceuticals
  • 130. Eurogentec
  • 131. Europe Pharmaceutical
  • 132. F4 Pharma
  • 133. Ferring Pharmaceuticals
  • 134. FirstString Research
  • 135. Follicum
  • 136. Formac Pharmaceuticals
  • 137. Frontier Biotechnologies
  • 138. Genervon Biopharmaceuticals
  • 139. Genosphere
  • 140. Genpro Biotech
  • 141. GenScript
  • 142. Genus Oncology
  • 143. Gila Therapeutics
  • 144. GlaxoSmithKline
  • 145. GlioCure
  • 146. GLyPharma
  • 147. GlyTech
  • 148. GP Pharm
  • 149. Grace
  • 150. Green Chemistry and Enabling Technologies
  • 151. IBMM Peptide
  • 152. Grey Matter Research Foundation
  • 153. GYRUS Pharma
  • 154. HAMLET Pharma
  • 155. Hemmo Pharmaceuticals
  • 156. HighTide Therapeutics
  • 157. Hybio Pharmaceutical
  • 158. iBio
  • 159. i-DNA Biotechnology
  • 160. IDP Pharma
  • 161. ILC Therapeutics
  • 162. ILS (A subsidiary of Otsuka Chemical)
  • 163. Imcyse
  • 164. ImmuPharma
  • 165. Innovagen
  • 166. Inotrem
  • 167. Intavis Peptide Services
  • 168. Integrity Bio
  • 169. InterK Peptide Therapeutics
  • 170. Iris Biotech
  • 171. Issar Pharmaceuticals
  • 172. Jitsubo
  • 173. JPT Peptide Technologies
  • 174. Kaijie Peptide
  • 175. Kalos Therapeutics
  • 176. KareBayTM Biochem
  • 177. KeyBioscience
  • 178. Kinexus
  • 179. KriSan Biotech
  • 180. KYTHERA Biopharmaceuticals
  • 181. La Jolla Pharmaceutical
  • 182. Lassogen
  • 183. LifeTein
  • 184. Longevity Biotech
  • 185. Lonza
  • 186. Lyotex
  • 187. MedImmune
  • 188. MElkin Pharmaceuticals
  • 189. MeSCue-Janusys
  • 190. Mimotopes
  • 191. MuseChem
  • 192. Nanomerics
  • 193. Nanos
  • 194. Natco Pharma
  • 195. National Cancer Institute
  • 196. NervGen
  • 197. Neuland Laboratories
  • 198. Neuro-Bio
  • 199. New England Peptide
  • 200. NextPharma
  • 201. NoNO
  • 202. NovaCell Technology
  • 203. Novavax
  • 204. Novetide
  • 205. Novo Nordisk
  • 206. NSJ Prayog Life Sciences
  • 207. NUMAFERM
  • 208. ONL Therapeutics
  • 209. OPKO Health
  • 210. Oramed Pharmaceuticals
  • 211. ORPEGEN Peptide Chemicals
  • 212. Oryn Therapeutics
  • 213. Ovoca Bio
  • 214. Oxalo Therapeutics
  • 215. Oxurion
  • 216. Palatin Technologies
  • 217. Pepceuticals
  • 218. PEPDesign
  • 219. Pepscan
  • 220. PEP-Therapy
  • 221. Peptide 2.0
  • 222. Peptide Institute
  • 223. Peptide Sciences
  • 224. Peptide Synthetics
  • 225. peptides&elephants
  • 226. Peptilogics
  • 227. PeptiStar
  • 228. Peptron
  • 229. Pfanstiehl
  • 230. PharmaMar
  • 231. Phoenix Pharmaceuticals
  • 232. piCHEM
  • 233. PIN Pharma
  • 234. Piramal Pharma Solutions
  • 235. PolyPeptide
  • 236. Polyphor
  • 237. PREVITALICA
  • 238. Priavoid
  • 239. PrimaPharma
  • 240. Primm Biotech
  • 241. Priveel peptides
  • 242. ProImmune
  • 243. ProLynx
  • 244. Promore Pharma
  • 245. ProNeurogen
  • 246. Protagenic Therapeutics
  • 247. Protagonist Therapeutics
  • 248. Proteimax
  • 249. Proteogenix
  • 250. ProvePharm
  • 251. Pulmotect
  • 252. Quantum Hi-Tech (China) Biological
  • 253. Radius Health
  • 254. Rani Therapeutics
  • 255. RegeneRx Biopharmaceuticals
  • 256. Revolo Biotherapeutics
  • 257. Rhythm Pharmaceuticals
  • 258. rPeptide
  • 259. RS Synthesis
  • 260. Salix Pharmaceuticals
  • 261. Sanofi
  • 262. Santhera Pharmaceuticals
  • 263. Sapience Therapeutics
  • 264. SBS Genetech
  • 265. Scancell
  • 266. Schafer-N
  • 267. Scilight-Peptide
  • 268. ScinoPharm
  • 269. Seachaid Pharmaceuticals
  • 270. Sekisui Medical
  • 271. Senn Chemicals
  • 272. Serpin Pharma
  • 273. Severn Biotech
  • 274. Shengnuo Peptide
  • 275. Shenzhen JYMed Technology
  • 276. Sinopep
  • 277. Soligenix
  • 278. Soricimed Biopharma
  • 279. Space Peptides
  • 280. STA Pharmaceutical (A subsidiary of WuXi AppTec)
  • 281. Stealth BioTherapeutics
  • 282. Sussex Research
  • 283. Symbiosis Pharmaceutical
  • 284. Synex
  • 285. SYNG Pharmaceuticals
  • 286. EOC Pharma
  • 287. Takeda
  • 288. TCG
  • 289. TearSolutions
  • 290. TheraSource
  • 291. Theratechnologies
  • 292. Topas Therapeutics
  • 293. Tufts University Core Facility
  • 294. TwoToBiotech
  • 295. UCB Pharma
  • 296. Ulster University
  • 297. UNC Lineberger Comprehensive Cancer Center
  • 298. United Biosystems
  • 299. US Biological
  • 300. USV
  • 301. Valliscor
  • 302. Vault Pharma
  • 303. Vaxeal
  • 304. Viatem
  • 305. Vivtide
  • 306. Wilshire Technologies
  • 307. Wuhan Jetide Biotech
  • 308. Xaia Custom Peptides
  • 309. Xigen
  • 310. Zealand Pharma
  • 311. Zhangzhou Sinobioway Peptide
  • 312. Zhejiang Peptides Biotech
  • 313. Zucara Therapeutics